seed
therapeutics
launches
protein
degradation
research
platform
appoints
edward
dongheng
liu
chief
financial
officer
new
york
globe
newswire
seed
therapeutics
company
seed
therapeutics
global
research
company
beyondspring
subsidiary
focused
harnessing
engineering
molecular
glue
targeted
protein
degradation
tpd
platform
attack
previously
believed
undruggable
targets
today
announced
company
appointment
edward
dongheng
liu
chief
financial
officer
tpd
technology
targets
diseases
treated
traditional
pharmaceutical
approaches
percent
protein
targets
believed
contribute
causing
disease
considered
undruggable
seed
therapeutics
employs
molecular
glue
platform
cellular
ubiquitination
system
potentially
target
proteins
seed
therapeutics
one
global
companies
leading
charge
molecular
protein
degradation
research
said
lan
huang
ceo
seed
therapeutics
particularly
close
field
solved
first
ligase
world
years
ago
research
fellow
memorial
sloan
kettering
cancer
center
inspired
see
tpd
field
blossoming
major
force
behind
current
innovative
drug
discovery
efforts
cfo
edward
lead
seed
therapeutics
financial
efforts
strengthen
company
global
leadership
tpd
field
vast
global
experience
investment
banking
corporate
development
entrepreneurship
crucial
company
liu
served
beyondspring
cfo
since
played
instrumental
role
overall
financial
strategies
activities
successfully
enhanced
beyondspring
shareholder
base
built
strong
investor
banking
relationships
significantly
improved
stock
liquidity
additionally
investor
beyondspring
since
joining
beyondspring
liu
served
partner
executive
director
epiphron
capital
private
equity
firm
well
held
leadership
positions
global
financial
institutions
include
senior
vice
president
vice
president
investment
banking
capital
markets
jefferies
vice
president
investment
banking
morgan
liu
led
financing
transactions
clients
across
sectors
total
transaction
value
exceeding
billion
seed
therapeutics
differentiated
molecular
glue
protein
degradation
research
platform
enable
discovery
new
therapies
treat
diseases
currently
solutions
added
liu
also
serves
cfo
china
beyondspring
new
responsibilities
seed
therapeutics
allow
us
help
bring
innovative
medicines
patients
need
current
therapies
fall
learn
please
visit
seed
therapeutics
seed
therapeutics
subsidiary
beyondspring
nasdaq
bysi
global
research
company
focused
harnessing
engineering
molecular
glue
targeted
protein
degradation
attack
previously
believed
undruggable
targets
backed
comprehensive
intellectual
property
portfolio
seed
therapeutics
mission
positively
impact
human
health
creating
novel
protein
degradation
therapeutics
treat
various
severe
diseases
currently
limited
options
patients
families
ongoing
collaborations
academic
experts
field
seed
therapeutics
establishing
growing
pipeline
novel
drug
candidates
path
potential
clinical
commercial
success
protein
degradation
majority
approved
treatments
diseases
act
binding
molecular
targets
inside
outside
cells
impact
signaling
actions
cellular
targets
drugs
drug
candidates
discovered
typical
strategy
predominately
bind
specific
pocket
targeted
protein
structure
inhibit
function
proteins
importantly
percent
proteins
thought
involved
diseases
likely
undruggable
pockets
small
molecular
binding
drug
development
strategy
benefit
therapeutic
development
many
serious
indications
therefore
suffered
due
lack
proteins
druggable
rather
lack
understanding
disease
biology
seed
therapeutics
overcoming
challenge
developing
novel
therapies
aim
degrade
proteins
mutant
kras
proteins
responsible
resistance
therapies
inhibit
function
groundbreaking
strategy
potential
offer
meaningful
benefits
millions
patients
suffering
serious
conditions
cancer
cns
diseases
infectious
diseases
cautionary
note
regarding
statements
press
release
includes
statements
historical
facts
words
expect
anticipate
plan
believe
design
may
future
estimate
predict
objective
goal
variations
thereof
variations
words
similar
expressions
intended
identify
statements
statements
based
beyondspring
current
knowledge
present
beliefs
expectations
regarding
possible
future
events
subject
risks
uncertainties
assumptions
actual
results
timing
events
could
differ
materially
anticipated
statements
result
several
factors
including
limited
difficulties
raising
anticipated
amount
needed
finance
company
future
operations
terms
acceptable
company
unexpected
results
clinical
trials
delays
denial
regulatory
approval
process
results
meet
expectations
regarding
potential
safety
ultimate
efficacy
clinical
utility
product
candidates
increased
competition
market
risks
described
beyondspring
recent
form
file
securities
exchange
commission
statements
made
herein
speak
date
release
beyondspring
undertakes
obligation
update
publicly
statements
reflect
subsequent
events
circumstances
except
otherwise
required
law
media
contacts
caitlin
kasunich
raquel
cona
kcsa
strategic
communications
ckasunich
rcona
